Plain-English translation of NCT06283966 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding budesonide to an inhaler medication (glycopyrronium and formoterol fumarate) can better protect the hearts and lungs of people with COPD. You would use this three-part inhaler twice a day and be compared to people using a two-part version of the same inhaler, to see if the medication with budesonide offers better protection against serious heart and lung events.
People with COPD often have heart disease or heart disease risk factors, and serious heart and lung events can be life-threatening. Researchers want to know if this medication can reduce those risks more effectively than the current standard treatment.
You likely qualify if…
You likely don't qualify if…
You would visit the research site multiple times (or participate in virtual visits) to receive your assigned inhaler and have your heart and lung health monitored through breathing tests and blood work. You would use your inhaler twice daily as directed and report back to the study team if you experience any serious health events. The study will continue until a certain number of heart or lung events occur across all participants, which could take several months to years.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States